These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33517002)

  • 41. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
    Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
    Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
    Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
    Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
    Chen Z; Wang ZC; Yan XQ; Wang PF; Lu XY; Chen LW; Zhu HL; Zhang HW
    Bioorg Med Chem Lett; 2015 May; 25(9):1947-51. PubMed ID: 25866240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Boronic acid derivative activates pyruvate kinase M2 indispensable for redox metabolism in oral cancer cells.
    Rihan M; Vineela Nalla L; Dharavath A; Patel S; Shard A; Khairnar A
    Bioorg Med Chem Lett; 2022 Mar; 59():128539. PubMed ID: 35007726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
    Soliman AM; Alqahtani AS; Ghorab M
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
    J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, biological evaluation, and docking studies of new pyrazole-based thiourea and sulfonamide derivatives as inhibitors of nucleotide pyrophosphatase/phosphodiesterase.
    Ullah S; El-Gamal MI; Zaib S; Anbar HS; Zaraei SO; Sbenati RM; Pelletier J; Sévigny J; Oh CH; Iqbal J
    Bioorg Chem; 2020 Jun; 99():103783. PubMed ID: 32224334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
    Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
    Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
    Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
    Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.
    Puckett DL; Alquraishi M; Chowanadisai W; Bettaieb A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights.
    Al-Sanea MM; Elkamhawy A; Paik S; Lee K; El Kerdawy AM; Syed Nasir Abbas B; Joo Roh E; Eldehna WM; Elshemy HAH; Bakr RB; Ali Farahat I; Alzarea AI; Alzarea SI; Alharbi KS; Abdelgawad MA
    Bioorg Med Chem; 2020 Jul; 28(13):115525. PubMed ID: 32371117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2).
    Xu Y; Liu XH; Saunders M; Pearce S; Foulks JM; Parnell KM; Clifford A; Nix RN; Bullough J; Hendrickson TF; Wright K; McCullar MV; Kanner SB; Ho KK
    Bioorg Med Chem Lett; 2014 Jan; 24(2):515-9. PubMed ID: 24374270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activators of PKM2 in cancer metabolism.
    Warner SL; Carpenter KJ; Bearss DJ
    Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
    Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
    Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors.
    Halawa AH; Eskandrani AA; Elgammal WE; Hassan SM; Hassan AH; Ebrahim HY; Mehany ABM; El-Agrody AM; Okasha RM
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.